Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  PAREXEL International Corporation ... be presenting at the Goldman Sachs Healthcare Conference in ... and Chief Executive Officer, will be making a presentation ... PDT on Tuesday, June 9, 2015. A ... the "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:5/26/2015)...  OrthoAccel ® Technologies, Inc., the leader in non-invasive, ... in response to continued demand from orthodontists and patients ... 2,500 practice locations in the U.S. and ... is the only FDA-cleared Class II medical device ... by as much as 50 percent.  ...
(Date:5/26/2015)... , May 26, 2015  Halyard Health, Inc. (NYSE: ... and chief executive officer will present at the 2015 Morgan ... at approximately 8:45 a.m., CDT on Thursday, June 4. ... available in the Investors section of the Halyard Health website ... site. About Halyard Health: Halyard ...
Breaking Medicine Technology:PAREXEL International To Present At Goldman Sachs Healthcare Conference 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 3
... Targetbase , a leading ... understanding consumer data, translating that data into intelligence, and ... today announced that Peter Dannenfelser has joined the agency ... pharmaceutical marketing executive with extensive experience at healthcare companies ...
... Inc. is changing its name to Xeridiem Medical Devices, ... "Although we,re changing our name, we will continue ... development, and manufacturing services that we,ve provided for nearly ... President. "Our mission remains the same - to improve healthcare ...
Cached Medicine Technology:Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 3MRI Medical Inc. Changing Name to Xeridiem Medical Devices, Inc. 2
(Date:5/27/2015)... 2015 Water, Inc. , ... products, has announced that its elite BG-12000 Body ... first to pass the new NSF/ANSI Standard 401 ... monumental, proving that the BG-12000 by Water, Inc. ... medications, and chemicals used in manufacturing that are ...
(Date:5/27/2015)... May 27, 2015 This year, Mental ... awareness campaign and encouraging those affected to seek assistance before ... Health (NAMI), one in five children, ages 13 to ... Additionally, 50% of all cases of mental illness within one's ... it is essential to seek help before reaching a critical ...
(Date:5/27/2015)... Palm Springs, CA (PRWEB) May 27, 2015 ... public health campaign dedicated to ending the spread of ... digital advocates at the 1st Annual YesGTCV Social Ambassador ... from 6 – 7 p.m. PST. , A first ... reward Get Tested Coachella Valley’s most active online influencers ...
(Date:5/27/2015)... Kudolife , a free diet and ... release available at the App Store today. This ... calories and activities with a glance by utilizing machine ... for accurate tracking. , The complete lifestyle iOS app ... which will allow users to proactively stay on track ...
(Date:5/27/2015)... One of America's most cherished actors, James ... America” that takes a look at the topic of ... an abnormal heart rhythm. Those who suffer from atrial ... much too quickly. , This new segment will take ... effort to inform viewers about possible signs that commonly ...
Breaking Medicine News(10 mins):Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 2Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 3Health News:The Glenholme School Observes Mental Health Awareness Month 2Health News:The Glenholme School Observes Mental Health Awareness Month 3Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 3Health News:Kudolife Launches into Apple Watch App Market with Newest Release 2Health News:Kudolife Launches into Apple Watch App Market with Newest Release 3
... experts say , , FRIDAY, Sept. 28 (HealthDay News) -- ... autoimmune disease lupus is building up steam, a group ... researchers from across the United States spoke at a ... of the improving outlook for patients with systemic lupus ...
... of,Labor,s Occupational Safety and Health Administration (OSHA) today ... Grants to 55 nonprofit,organizations for safety and health ... are at the heart of our compliance assistance,efforts ... Labor for,OSHA Edwin G. Foulke Jr. "The Harwood ...
... Association (PCMA) released the following statement today,supporting legislation ... Energy and Commerce Subcommittee on Health: "PCMA ... week that would fix the flawed Average Manufacturer ... Act. "PCMA supports the decision to remove ...
... Laboratories Inc.,(NYSE: MYL ) ("Mylan") announced today that ... previously announced cash tender offers and consent,solicitations for its ... Notes") and 6.375% Senior Notes due 2015 (CUSIP Nos. ... Notes, the,"Notes"), which are being conducted pursuant to the ...
... is giving a,keynote address or visiting on the sidewalk ... possibility. "Only in America could someone like me ... laugh, "I,m a physically disabled woman whose,father is a ... I,m running for Town Council as a Republican." ...
... September 28, 2007 - Oncolytics Biotech Inc. (Oncolytics) ... interim results from a U.K. Phase Ia/Ib ... with advanced or metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in Birmingham, ...
Cached Medicine News:Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:U.S. Labor Department Awards $10.1 Million for Safety and Health Training Grants 2Health News:Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015 2Health News:Humor and Hope Sustain NJ Woman Through Disabling Movement Disorder, Election Campaign 2Health News:Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials 2Health News:Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: